ProMetic Life Sciences (PLI) Given Consensus Recommendation of “Buy” by Brokerages

Shares of ProMetic Life Sciences (TSE:PLI) have received an average recommendation of “Buy” from the seven brokerages that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and three have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is C$1.89.

PLI has been the subject of several analyst reports. National Bank Financial downgraded shares of ProMetic Life Sciences from a “sector perform” rating to an “underperform” rating and cut their target price for the company from C$2.00 to C$1.00 in a research note on Thursday, March 29th. Canaccord Genuity lowered their price target on ProMetic Life Sciences from C$4.00 to C$2.00 in a report on Tuesday, April 3rd. TD Securities lowered their price target on ProMetic Life Sciences from C$3.50 to C$2.00 in a report on Monday, April 2nd. Royal Bank of Canada lowered their price target on ProMetic Life Sciences from C$3.50 to C$2.00 and set an “outperform” rating for the company in a report on Monday, April 2nd. Finally, CIBC lowered their price target on ProMetic Life Sciences from C$2.15 to C$0.60 in a report on Monday, April 2nd.

Shares of ProMetic Life Sciences opened at C$0.74 on Friday, MarketBeat.com reports. ProMetic Life Sciences has a twelve month low of C$0.63 and a twelve month high of C$2.16.

ProMetic Life Sciences (TSE:PLI) last announced its earnings results on Wednesday, March 28th. The company reported C($0.05) earnings per share for the quarter. ProMetic Life Sciences had a negative net margin of 73.85% and a negative return on equity of 48.83%. The firm had revenue of C$6.60 million during the quarter.

In other news, Director Dwun-Hou Chen sold 108,566 shares of the business’s stock in a transaction dated Friday, April 6th. The stock was sold at an average price of C$0.86, for a total transaction of C$93,366.76.

About ProMetic Life Sciences

ProMetic Life Sciences Inc, a biopharmaceutical company, develops bioseparations, plasma-derived therapeutics, and small-molecule therapeutic products. It operates through three segments: Small-Molecule Therapeutics, Plasma-Derived Therapeutics, and Bioseparation Technologies. The company offers its technology platform for purification of biologics, drug development, proteomics, and elimination of pathogens; and develops small molecule therapeutic products targeting unmet medical needs in the fields of fibrosis, inflammation, autoimmune diseases, oncology, and nephropathies.

Analyst Recommendations for ProMetic Life Sciences (TSE:PLI)

Receive News & Ratings for ProMetic Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply